Join Chloe Atreya, MD, PhD and Alan P. Venook, MD from UCSF Helen Diller Family Comprehensive Cancer Center as they present their multidisciplinary expertise on a range of cases pertaining to metastatic colorectal cancer (mCRC).

The management of mCRC involves a continuum of care in which patients are exposed sequentially to a variety of active agents either in combinations or as single agents. The choice of therapy is based on the goals of treatment (i.e. eradication of micrometastases in resectable patients, tumor shrinkage to obtain resectability, slowing of disease in unresectable patients), the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, and the mutational status of the tumor. In discussing treatment options with patients with mCRC, clinicians need to consider the goals of therapy, the different efficacy and toxicity profiles of the drugs, the patient’s previous treatment history, the relevant tumor markers, and patient preferences. Clinicians must be aware of new data regarding extended RAS testing as well as the combination of cetuximab with FOLFOX in different mCRC settings to effectively lead these conversations.